L

Lyla J. Stanland

Tenax Therapeutics (United States)

ORCID: 0000-0002-1732-5210

Publishes on Cancer Mechanisms and Therapy, Pancreatic and Hepatic Oncology Research, PI3K/AKT/mTOR signaling in cancer. 121 papers and 133 citations.

PubIndex Score78Top 22% · early-careerHow it's scored

121Publications

133Total Citations

First publication: 2023

Cancer Mechanisms and Therapy Pancreatic and Hepatic Oncology Research PI3K/AKT/mTOR signaling in cancer Peptidase Inhibition and Analysis Chronic Lymphocytic Leukemia Research

Top publicationsby citations

CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i> -Mutant Gastric Cancer

Lyla J. Stanland, Micah A. Luftig, Yunqiang Chu et al.|Molecular Cancer Research|2023

Cited by 13

Data from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer

Lyla J. Stanland, Micah A. Luftig, Kris C. Wood et al.|Unknown|2023

Cited by 1

Figure S1 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Lyla J. Stanland, Micah A. Luftig, Hazel X. Ang et al.|Unknown|2023

Cited by 0

Table S9 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Lyla J. Stanland, Micah A. Luftig, Hazel X. Ang et al.|Unknown|2023

Cited by 0

Table S7 from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i>-Mutant Gastric Cancer

Lyla J. Stanland, Micah A. Luftig, Hazel X. Ang et al.|Unknown|2023

Cited by 0